NCT05773586 is a Phase 1 clinical trial of APG-5918 in Anemia, sponsored by Ascentage Pharma Group Inc..

Who is sponsoring NCT05773586?

NCT05773586 is sponsored by Ascentage Pharma Group Inc..

What drugs are being tested in NCT05773586?

Interventions in NCT05773586: APG-5918, Placebo.

Is NCT05773586 still recruiting?

NCT05773586 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT05773586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918.

Recruiting now Phase 1 Last updated 15 April 2026

What this trial tests

Phase 1 trial testing APG-5918 in Anemia in 105 participants. Currently enrolling.

Timeline

13 March 2023

Primary endpoint
31 December 2027

15 July 2028

Quick facts

Lead sponsor	Ascentage Pharma Group Inc.
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	105
Start date	13 March 2023
Primary completion	31 December 2027
Estimated completion	15 July 2028
Sites	2 locations across China

Drugs / interventions tested

APG-5918 — full drug profile →
Placebo

Conditions studied

Anemia — all drugs for Anemia →

Sponsor

Ascentage Pharma Group Inc. — full company profile →

Who can join

18 and older, any sex, with Anemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics and efficacy of APG-5918 in Healthy Subjects or Anemic Patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The roles of EZH2 in cancer and its inhibitors.
Liu Y, Yang Q. · · 2023 · cited 100× · PMID 37148376 · DOI 10.1007/s12032-023-02025-6
Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q, Kumar A, Wu D, Zhou J. · · 2024 · cited 14× · PMID 38642703 · DOI 10.1016/j.drudis.2024.103986

Verify or expand the search:

Other trials of APG-5918

Trials testing the same drug.

NCT05415098 — Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas · Phase 1 · unknown

Other recruiting trials for Anemia

Currently open trials in the same condition.

NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
NCT07400796 — Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia · recruiting

Other Ascentage Pharma Group Inc. trials

Trials by the same sponsor.

NCT07282093 — Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment · Phase 1 · recruiting
NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
NCT06389292 — A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia · Phase 3 · recruiting
NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
NCT06051409 — A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05773586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ascentage Pharma Group Inc.
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05773586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing